Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia
Accepted: 28 April 2020
HTML: 97
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus itself, but by an overactive inflammatory state. In fact, in some people the immune system goes into overdrive and launches a large-scale assault on the tissue known as cytokine storm. This excessive inflammatory/immune reaction can damage tissue and eventually kill people. Evidence shows that blocking such cytokine storms can be effective and trials are under way to test drugs that act by reducing cytokine response, such as tocilizumab and sarilumab which bind interleukin 6 (IL-6), or anakinra which is the interleukin 1 receptor antagonist (IL-1). However, other drugs that block the cytokine cascade can also be considered. In this article we describe the scientific and molecular motivation for the use of drugs that act by modulating the hyperactive inflammatory system in severe patients suffering from SARS-CoV-2, considering in particular an old drug that has been in use for many years for other therapeutic indications such as colchicine, and that could be favorable to its use, with low cost and good tolerability.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
-
Joshua Adedeji Bolarin, Mercy Adaramodu Oluwatoyosi, Joshua Iseoluwa Orege, Emmanuel Ayodeji Ayeni, Yusuf Ajibola Ibrahim, Sherif Babatunde Adeyemi, Bashir Bolaji Tiamiyu, Lanre Anthony Gbadegesin, Toluwanimi Oluwadara Akinyemi, Chuks Kenneth Odoh, Happiness Ijeoma Umeobi, Adenike Bernice-Eloise AdeoyeInternational Immunopharmacology : 2021
-
Antonio Vitiello, Francesco FerraraInternational Journal of Molecular Sciences : 2022
-
Antonio Vitiello, Chiara Pelliccia, Francesco FerraraSN Comprehensive Clinical Medicine : 2020
-
Parisa Shiri Aghbash, Hamed Ebrahimzadeh Leylabadlo, Hamidreza Fathi, Mohaddeseh Bahmani, Rojin Chegini, Hossein Bannazadeh Baghi, Alessandro GranitoCanadian Journal of Gastroenterology and Hepatology : 2022
-
Kemal Nas, Nuran Eryilmaz, Mehmet Faruk Geyik, Ayfer AltaşRheumatology International : 2021
-
Yijing Chu, Min Li, Mingze Sun, Jing Wang, Wan Xin, Lin XuFrontiers in Immunology : 2024
-
Angela E. Peter, B. V. Sandeep, B. Ganga Rao, V. Lakshmi KalpanaFrontiers in Pharmacology : 2021
-
Francesco Ferrara, Antonio VitielloWiener klinische Wochenschrift : 2021
-
Francesco Ferrara, Raffaele La Porta, Vilma D’Aiuto, Antonio VitielloIrish Journal of Medical Science (1971 -) : 2021
-
Francesco Ferrara, Antonio VitielloNaunyn-Schmiedeberg's Archives of Pharmacology : 2021
-
Antonio Vitiello, Francesco FerraraSN Comprehensive Clinical Medicine : 2020
-
Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, Nikhilesh Alahari, Suresh K. AlahariBiochemical Pharmacology : 2021
-
Antonio Vitiello, Raffaele La Porta, Vilma D’Aiuto, Francesco FerraraEgyptian Liver Journal : 2021
-
F. Ferrara, A. VitielloCardiovascular Toxicology : 2021
-
Sepideh Hejazi, Zohreh Jahani, Sepideh Elyasi, Davoud Salarbashi, Mona KabiriRecent Advances in Anti-Infective Drug Discovery : 2024